Research Article
Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study
Table 3
Characteristics of patients with active and inactive LN at each time point.
| | Parameters | Baseline | 2 months | 4 months | | Active LN (A) | A, | A, | A, | | Inactive LN (IA) | IA, | IA, | IA, |
| | Serum albumin | 37.78 ± 5.54 | 39 ± 5 | 37.5 ± 4.97 | | (35–50 g/L) | 41.88 ± 3.59 | 41.78 ± 3.20 | 41.02 ± 5.82 | | Intergroup p value | <0.001 | <0.001 | 0.01 |
| | Serum creatinine | 69 (IQR 33–252) | 72 (IQR 30–244) | 89.5 (IQR 43–244) | | (44–80 mol/L) | 63 (IQR 41–158) | 65 (IQR 37–168) | 63 (IQR 34–192) | | Intergroup p value | 0.29 | 0.36 | 0.004 |
| | eGFR | 93.61 ± 46.01 | 91 ± 49.16 | 75.04 ± 39.95 | | (>60 mL/min/1.73 m2) | 99.75 ± 31.54 | 98 ± 32.69 | 98.35 ± 35 | | Intergroup p value | 0.43 | 0.53 | 0.009 |
| | ESR | 38.5 (IQR 21–91) | 41 (IQR 22–92) | 32 (IQR 8–105) | | (mm/hr) | 33 (IQR 0–46) | 49 (IQR 10–103) | 36 (IQR 1–78) | | Intergroup p value | 0.37 | 0.86 | 0.36 |
| | Anti-dsDNA Ab titers | 35.18 (IQR 1.73–195.97) | 30.23 (IQR 0.74–267.61) | 41.53 (IQR 2.07–291.62) | | (<30 IU/dL) | 24.24 (IQR 0.81–279.21) | 14.37 (IQR 1.05–280) | 18.90 (IQR 0.95–262.21) | | Intergroup p value | 0.84 | 0.89 | 0.73 |
| | Serum C3 | 100.5 ± 36.39 | 102.25 ± 40.53 | 94.26 ± 26.67 | | (79–152 mg/dL) | 109.62 ± 39.94 | 106.37 ± 41.54 | 104.16 ± 33.04 | | Intergroup p value | 0.24 | 0.32 | 0.21 |
| | Serum C4 | 21.46 ± 12.82 | 21.14 ± 10.95 | 22.81 ± 10.19 | | (16–38 mg/dL) | 22.94 ± 11 | 23.95 ± 13.69 | 23.14 ± 9.48 | | Intergroup p value | 0.54 | 0.32 | 0.89 |
| | Proteinuria (uPCI) | 110 (IQR 10–510) | 130 (IQR 10–480) | 110 (IQR 10–510) | | (<20 mg/mmol creatinine) | 20 (IQR 10–50) | 20 (IQR 10–50) | 20 (IQR 10–30) | | Intergroup p value | <0.001 | <0.001 | <0.001 |
| | Urinary leucocytes/HPF ×106/L | 0 (0–20) | 0 (0–20) | 0 (0–20) | | | 0 (0–5) | 0 (0–15) | 0 (0–10) | | Intergroup p value | <0.001 | 0.30 | 0.007 |
| | Urinary | 0 (0–10) | 0 (0–20) | 0 (0–50) | | RBC/HPF ×106/L | 0 (0–5) | 0 (0–15) | 0 (0–30) | | Intergroup p value | <0.001 | 0.40 | 0.03 |
| | uMCP-1 | 9,317 (IQR 548–40,170) | 5,163 (IQR 1,953.79–18,458) | 7,288 (IQR 0–51,221) | | (pg/mg creatinine) | 3,682 (IQR 0–23.866) | 2,496 (IQR 0–13,412) | 2,220 (IQR 0–11,470) | | Intergroup p value | <0.001 | <0.001 | <0.001 |
| | SLEDAI-2K | 8 (IQR 0–18) | 6 (IQR 0–18) | 8 (IQR 0–20) | | (global: 0–105) | 2 (IQR 0–10) | 2 (IQR 0–12) | 2 (IQR 0–17) | | Intergroup p value | <0.001 | <0.001 | <0.001 |
| | SLEDAI-2K | 4 (IQR 0–16) | 4 (IQR 0–12) | 4 (IQR 0–16) | | (renal: 0–16) | 0 (IQR 0–3) | 0 (IQR 0–8) | 0 (IQR 0–12) | | Intergroup p value | <0.001 | <0.001 | <0.001 |
| | SLEDAI-2K | 4 (IQR 0–12) | 2 (IQR 0–10) | 4 (IQR 0–12) | | (extrarenal: 0–89) | 2 (IQR 0–10) | 2 (IQR 0–9) | 2 (IQR 0–8) | | Intergroup p value | 0.66 | 0.18 | 0.10 |
|
|
